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Background: Adipokines, including adipocyte fatty acid-binding protein (A-FABP), have been demonstrated to be
involved in the pathogenesis of atherosclerosis. In the present study, we investigated the association of circulating
A-FABP level with severity of myocardial perfusion abnormalities analyzed by Tl-201 dipyridamole single-photon
emission computed tomography.
Methods: A total of 170 patients with coronary artery disease (CAD) from cardiovascular clinics were enrolled in the
study. Serum A-FABP levels, echocardiography, and stress myocardial perfusion imaging results were analyzed.
Results: Compared with the patients with mild CAD (summed stress score [SSS] ≤ 8), those with moderate to
severe CAD (SSS > 8) had significantly higher A-FABP concentrations. However, the difference was attenuated in
the subgroup of patients with heart failure. In the correlation analyses, A-FABP level was correlated with age, body
mass index, waist circumference, levels of creatinine, fasting glucose, high-sensitivity C-reactive protein, N-terminal
pro-brain natriuretic peptide, adiponectin, and several echocardiographic parameters, including left ventricular
ejection fraction. Multivariate logistic regression analysis demonstrated that the A-FABP level was not only
associated with higher SSS (odds ratio, 1.30; 95% confidence interval [CI], 1.01–1.69; P = 0.048), but also an
independent risk factor for heart failure (odds ratio 2.71, 95% CI, 1.23–5.94; P = 0.013).
Conclusions: Serum A-FABP levels not only were associated with myocardial perfusion abnormalities and left
ventricular function, but also predicted the presence of heart failure in our patients with CAD.
Keywords: Adipocyte fatty-acid binding protein, Coronary artery disease, Single-photon emission computed
tomographyBackground
Insulin resistance is closely associated with cardio-
vascular disease and heart failure (HF), and dysregulated
adipokines, which are mainly released from adipose
tissues, suggesting possible links between these condi-
tions [1,2]. These adipokines, including adiponectin,
resistin, and leptin, are known to mediate important* Correspondence: wuyw0502@gmail.com; wsyang@ntu.edu.tw
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reproduction in any medium, provided the orinflammatory and metabolic responses [3-5]. Adipocyte
fatty-acid binding protein (A-FABP), also termed aP2, is
one of the most abundant intracellular lipid transport
proteins in mature adipocytes and macrophages. How-
ever, data from rodents and humans suggest that it is
also secreted into the bloodstream by adipose tissue [6].
In animal studies, A-FABP has been shown to regulate
many inflammatory cytokines, mediate lipotoxicity and
endoplasmic reticulum stress, and lead to endothelial
dysfunction by impairing the nitric oxide pathway [7-9].
Recent human studies have confirmed its association
with diabetes mellitus, non-alcoholic fatty liver disease,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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also an independent predictor of metabolic syndrome de-
velopment and coronary heart disease outcomes [10-14].
Two Asian studies showed a positive correlation be-
tween circulating A-FABP level and the severity of cor-
onary artery disease (CAD), as determined by coronary
angiography [15,16]. Tl-201 dipyridamole single-photon
emission computed tomography (SPECT) is currently
the standard tool in clinical CAD evaluation and demon-
strates the extent of myocardial scar and ischemic
burden. The aim of our study was to evaluate the correl-
ation of circulating A-FABP levels with SPECT results,
left ventricular function, and HF in CAD patients.
Methods
Study design
This cross-sectional study enrolled 170 consecutive pa-
tients with CAD from the cardiovascular outpatient
clinics at Taoyuan General Hospital and National Taiwan
University Hospital Hsin-Chu branch between July 2010
and June 2011. The study was approved by the institu-
tional review board of both hospitals, and written in-
formed consent was obtained from each patient before
enrollment. Eligible patients had at least one of the fol-
lowing: old myocardial infarction (> 6 months), coronary
revascularization, angiographic evidence of at least 50%
stenosis in 1 or more major coronary arteries, or evi-
dence of ischemia/scar on nuclear stress myocardial per-
fusion imaging. Patients were excluded if they had
evidence of acute inflammatory or infectious disease, de-
compensated liver disease, end-stage renal disease, active
malignancy, acute coronary syndrome, or a stroke within
the month before the investigation.
All demographic information, including height, weight,
waist measurements, cardiovascular risk factors, comor-
bid conditions, and a list of current medications were
obtained from the patients’ medical records. Two-
dimensional echocardiography and Tl-201 dipyridamole
SPECT, as previously described [17], were performed in
all participants. Left atrial dimension (LAd), left
ventricular end-diastolic dimension (LVEDd), left ven-
tricular end-systolic dimension (LVESd), interventricular
septal dimension (IVSd), and left ventricular ejection
fraction (LVEF) were evaluated and recorded in a
blinded manner. Regional myocardial uptake was nor-
malized and assessed using the 17-segment model and a
semiquantitative scoring system of defect severity with a
5-point scoring system (0 = normal, 1 = equivocal, 2 =
moderate, 3 = severe, and 4 = apparent absence of tracer
uptake) and extent, as recommended by the American
Society of Nuclear Cardiology [18]. Summed scores were
calculated from the segmental scores, including a
summed rest score (SRS; the sum of the 17 segmental
rest scores) and summed stress score (SSS; the sum ofthe 17 segmental stress scores). A summed difference
score (SDS; the difference between SSS and SRS) was
also calculated. CAD severity, which was determined by
SSS, was considered normal if the SSS < 4, mildly abnor-
mal if the SSS was between 4 and 8, and moderately to
severely abnormal if the SSS > 8. Image interpretation
according to these definitions was performed by 2 expe-
rienced readers. Divergent interpretations were classified
by consensus. The HF diagnosis was based on the cri-
teria established in the American College of Cardiology/
American Heart Association 2005 Guideline Update for
the Diagnosis and Management of HF [19].
Laboratory examinations included renal function,
fasting glucose, lipid profiles, high-sensitivity C-reactive
protein (hsCRP), and N-terminal pro-brain natriuretic
peptide (NT-proBNP). Glomerular filtration rate (GFR)
was estimated using the formula from Modification of
Diet in Renal Disease (MDRD). Serum A-FABP
(BioVendor Laboratory Medicine, Inc. Brno, Czech Re-
public) and adiponectin concentrations (B-Bridge Inter-
national, Inc., Cupertino, CA, USA) were analyzed by an
enzyme-linked immunosorbent assay method, according
to the manufacturer’s instructions.
Statistical analysis
Data are reported as mean ± SD for normal distributions
or as median with interquartile ranges for skewed
variables. Data that were not normally distributed were
logarithmically transformed before analysis. Group com-
parisons were performed by 2-sample t test. Univariate
relationships between A-FABP level and clinical vari-
ables, serum biomarkers, and parameters derived from
echocardiography and SPECT were assessed using
Pearson’s correlation coefficient (r). Differences in serum
A-FABP concentrations across SSS were compared by
one-way analysis of variance, followed by the Bonferroni
post-hoc test. To determine the independent predictors
of myocardial perfusion abnormality and HF, the various
parameters were included in multiple logistic regression
analyses (ordered logistic regression for SSS). Analyses
were performed using the STATA statistical software
(release 10.0, StataCorp, College Station, TX, USA). All
statistical tests were two-sided, where P < 0.05 was con-
sidered statistically significant.
Results
The characteristics of all the participants are shown in
Table 1. The mean age was 66.8 years, and 73% of the
patients were male. The prevalence of hypertension and
diabetes were 43% (n = 73) and 21% (n = 36), respect-
ively. Forty-six patients (27%) had a history of myocar-
dial infarction. Compared with those with mild CAD
(SSS ≤ 8), the patients with moderate to severe CAD
(SSS > 8) tended to be older, have a higher prevalence of
Table 1 Characteristics of coronary artery disease patients
Parameter All Mild CAD Moderate-severe CAD P value
(n =170) (SSS ≤8, n = 88) (SSS >8, n = 82)
Age (yr) 65.7 ± 13.6 64.0 ± 13.1 67.6 ± 13.9 0.09
Male gender (%) 115 (68%) 55 (63%) 50 (73%) 0.14
Body mass index (kg/m2) 24.9 ± 3.7 24.9 ± 3.5 24.9 ± 4.1 0.99
Waist (cm) 85 ± 11 86 ± 12 84 ± 11 0.41
Hypertension (%) 73 (43%) 36 (41%) 37 (45%) 0.58
Diabetes mellitus (%) 36 (21%) 14 (16%) 22 (27%) 0.08
Smoking (%) 43 (25%) 14 (16%) 29 (35%) 0.004
LVEF 0.61 ± 0.16 0.68 ± 0.13 0.53 ± 0.16 < 0.0001
Creatinine (mg/dL) 1.13 ± 0.45 1.03 ± 0.34 1.22 ± 0.53 0.005
Fasting glucose (mg/dL) 116 ± 45 110 ± 42 123 ± 47 0.07
Total cholesterol (mg/dL) 186 ± 47 184 ± 38 189 ± 57 0.58
HDL-C (mg/dL) 48 ± 16 51 ± 18 44 ± 12 0.006
LDL-C (mg/dL) 108 ± 34 105 ± 26 111 ± 41 0.25
ALT (U/L) 29 ± 19 27 ± 19 30 ± 20 0.18
hsCRP (ug/mL)* 2.3 (1.1, 8.2) 1.8 (0.6, 4.6) 3.0 (1.7, 11.9) 0.0005
NT-proBNP (ng/L)* 107 (42, 797) 63 (38, 127) 797 (129, 2572) < 0.0001
Adiponectin (mg/L)* 7.6 (5.2, 12.3) 7.4 (5.0, 10.0) 7.7 (5.3, 15.7) 0.13
A-FABP (ng/mL)* 26.2 (17.2, 40.1) 21.1 (16.2, 33.8) 32.4 (19.7, 48.5) 0.002
Medications
ACEi/ARBs 101 (59%) 34 (39%) 67 (82%) < 0.0001
Beta-blockers 57 (34%) 23 (26%) 34 (41%) 0.03
CCBs 39 (23%) 24 (27%) 15 (18%) 0.16
Diuretics 51 (30%) 14 (16%) 37 (45%) < 0.0001
Statins 36 (21%) 12 (14%) 24 (29%) 0.01
Metformin 12 (7%) 5 (6%) 7 (9%) 0.47
Values are expressed as mean ± S.D., median (25th - 75th percentile), or n (percentage).
*Logarithmically transformed before analysis.
ACEi/ARBs, angiotensin-converting enzyme inhibitor / angiotensin II receptor blockers; A-FABP, adipocyte fatty acid-binding protein, ALT, alanine aminotransferase;
CCBs, calcium channel blockers; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol;
LVEF, left ventricular ejection fraction.
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hsCRP, NT-proBNP, and A-FABP levels were also signifi-
cantly higher in the patients with moderate to severe
CAD. Among these patients, 34% (n = 58) had a clinical
diagnosis of heart failure with New York Heart Associ-
ation (NYHA) functional class II to IV. The patients with
HF had significantly higher serum NT-proBNP and hsCRP
levels than those without HF (P < 0.001 and P < 0.003,
respectively). Adiponectin and A-FABP concentrations
were also significantly higher in the patients with HF (HF
vs. non-HF: median level, adiponectin, 12.1 vs. 6.5 mg/L,
P < 0.0001; A-FABP, 34.8 vs. 21.0 ng/mL, P < 0.0001).
Table 2 shows the results of the correlation analysis
between the sex-adjusted A-FABP level and other clin-
ical parameters. In the overall patient population, after
the adjustment for sex, the A-FABP level was positively
correlated with age, body mass index (BMI), waistcircumference, levels of serum creatinine, fasting glu-
cose, high-density lipoprotein cholesterol (HDL-C),
hsCRP, adiponectin, and NT-proBNP, but negatively cor-
related with MDRD-GFR. Among the parameters de-
rived from echocardiography, A-FABP level was
inversely correlated with LVEF (r = −0.33, P < 0.0001),
but positively correlated with LVEDd, LVESd, LAd, and
IVSd.
In the analysis of SPECT results, SRS, SSS, and SDS
were regarded as indicators of myocardial scar, CAD
severity, and ischemic burden, among which SSS and
SDS showed a positive correlation with A-FABP levels
(r = 0.19 and 0.17, respectively; Table 2). The patients
with a high scar burden (SRS ≥ 4) had significantly
higher A-FABP levels (median, 31.6 vs. 21 ng/mL,
P = 0.006) than those with low or no scar burden (SRS
< 4). Compared with those with normal SSS (SSS < 4), a
Table 2 Correlation of sex-adjusted A-FABP levels with
biochemical parameters, echocardiographic indexes and
myocardial perfusion abnormalities
r P
Age 0.33 < 0.0001
Body mass index 0.31 0.0001
Waist circumference 0.36 < 0.0001
GFR −0.48 < 0.0001
Fasting glucose 0.18 0.024




NT-proBNP* 0.49 < 0.0001
Adiponectin* 0.20 0.019
Echocardiography
LVEF −0.33 < 0.0001
LVEDd 0.29 0.0002
LVESd 0.35 < 0.0001
LAd 0.33 0.0003
IVSd 0.40 < 0.0001
SPECT
Summed rest score (SRS) 0.13 0.088
Summed stress score (SSS) 0.19 0.013
Summed difference score (SDS) 0.17 0.027
* Logarithmically transformed before analysis.
GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol;
IVSd, interventricular septal dimension; LAd, left atrial dimension; LVEDd, left
ventricular end-diastolic dimension; LVESd, left ventricular end-systolic
dimension; LVEF, left ventricular ejection fraction; LDL-C: low-density
lipoprotein cholesterol.
Figure 1 Association between serum A-FABP concentration and
coronary artery disease severity determined by summed stress
score (SSS). Normal: SSS < 4, mildly abnormal: 4 ≤ SSS ≤ 8,
moderately to severely abnormal: SSS > 8.
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patients with more extensive CAD (SSS ≥ 4, P = 0.008;
Figure 1). Multivariate ordered logistic regression, using
SSS (normal, mildly abnormal, and moderately to se-
verely abnormal) as dependent variable, was performed
to investigate the association of A-FABP level and myo-
cardial perfusion abnormality. After adjustment for age,
sex, hypertension, BMI, smoking status, level of fasting
glucose, creatinine, low-density lipoprotein cholesterol
(LDL-C), and hsCRP, A-FABP level was still an inde-
pendent predictor of higher SSS (odds ratio, 1.30 per
10-ng/mL increase; 95% confidence interval [CI], 1.01–
1.69; P = 0.048). However, we further analyzed the associ-
ation between A-FABP level and myocardial perfusion
abnormalities in the subgroups of the patients with and
without HF. The differences in A-FABP levels between
patients with high and low SSS, and also SRS, were signifi-
cantly attenuated in those with concomitant HF (Table 3).
Finally, multiple logistic regression analysis was
performed to accurately evaluate the relationship betweenA-FABP level and HF in the subjects with CAD. A-FABP
level was also independently associated with the presence
of HF, with an odds ratio of 2.71 (95% CI, 1.23–5.94;
P = 0.013) for each 10-ng/mL increase (Table 4).
Discussion
Our study demonstrated that serum A-FABP levels were
associated with CAD severity, as determined by SPECT.
We also found that the patients with HF had higher
A-FABP levels than those without HF. After multivariate
adjustment, A-FABP was an independent predictor of
myocardial perfusion abnormalities and HF. However,
the correlations between A-FABP level and myocardial
perfusion abnormalities were attenuated in the subgroup
of patients with HF.
A-FABP expression is known to be a key proinflam-
matory mediator that links obesity with cardiovascular dis-
ease. Data from animal to human studies all support its
pathological roles in atherosclerosis. In apoE knockout
mice, A-FABP deficiency resulted in a marked reduction
of aortic atherosclerotic lesions [20]. In addition, pharma-
cological inhibition of A-FABP also rendered significant
protection against atherosclerotic plaque formation [21].
Depletion of A-FABP expression prevented oxidized LDL-
induced foam cell formation by increasing cholesterol
efflux and also inhibited IkB kinase/NF-kB activity. This
finding further supported the proatherogenic effects of
A-FABP in macrophages. In addition, A-FABP inhibited
eNOS activation and nitric oxide production in vascular
endothelial cells, which led to endothelial dysfunction.
This suppressive effect was reversed by treatment with an
A-FABP inhibitor [9,22]. In human studies, A-FABP is
known to be involved in metabolic syndrome and cardio-
vascular diseases. Circulating A-FABP levels have been
Table 3 Serum A-FABP distribution according to summed stress score, summed rest score and heart failure (HF)
condition
A-FABP (ng/mL)
All (n = 170) Non-HF (n = 112) HF (n = 58)
Summed stress score
SSS ≤ 8 21.1 (16.2, 33.8) P = 0.002 20.6 (15.5, 31.6) P = 0.037 35.1 (29.1, 58.3) P = 0.801
SSS > 8 32.4 (19.7, 48.5) 27.6 (16.2, 41.0) 34.5 (23.2, 53)
Summed rest score
SRS < 4 21 (15.3, 33.9) P = 0.006 20.6 (14.5, 32.0) P = 0.039 33.9 (28.0, 74.3) P = 0.760
SRS ≥ 4 31.6 (19.2, 45.7) 25.7 (17.1, 40.7) 35.0 (22.4, 53.6)
Presented with median (25th - 75th percentile) and logarithmically transformed before analysis.
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atherosclerosis, with the number of diseased vessels, and
with plaque burden of coronary arteries [15,16,23,24]. It is
also an important predictor of cardiovascular outcomes in
patients with coronary heart disease, acute ischemic
stroke, and end-stage renal disease [14,23,25]. Locally
expressed A-FABP in atherosclerotic plaques also reduces
plaque stability [26].
We also found an association between circulating
A-FABP level and metabolic components. A-FABP level
showed a positive correlation with waist circumference
and fasting glucose level but a negative correlation with
HDL-C. A weak correlation was also observed between
concentrations of A-FABP and adiponectin, another
well-documented insulin resistance marker. The
A-FABP concentration also correlated positively with the
inflammatory marker hsCRP, as previous studies have
demonstrated. There were significant differences in
A-FABP levels between men and women. Two Asian
studies made different conclusions about the relation-
ship of A-FABP and CAD in different sexes. In our
study, the differences in A-FABP levels between patients
with mild and severe CAD were consistent, although the
differences were more significant in women (median,
44.6 vs. 26.3 ng/mL, P = 0.0006). Previous studies have
also shown that atorvastatin and olmesartan treatment
lowered circulating A-FABP levels [27,28]. The higher
A-FABP levels in our patients treated with statins and
angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers might be related to the higherTable 4 Multiple logistic regression analysis showing odds ra
artery disease
Model A-FABP (per 10 ng/mL increase)
Model 1 Adjusting for age and sex
Model 2 Adjusting for age, sex, BMI, smoking, hypertension,
fasting glucose, LDL-C, creatinine and hsCRP
Model 3 Adjusting for age, sex, BMI, smoking, hypertension, fasting
creatinine, hsCRP, adiponectin, SSS, SRS, ACEi/ARBs, diuret
ACEi/ARBs, angiotensin-converting enzyme inhibitor / angiotensin II receptor blocke
low-density lipoprotein cholesterol; SRS, summed rest score; SSS, summed stress scprevalence of metabolic syndrome, severe CAD, and ad-
vanced HF. It is interesting that both HF and non-HF
subgroup patients taking thiazide diuretics had signifi-
cantly higher A-FABP concentrations. Thus, the effects
of thiazide diuretics, which are known to cause meta-
bolic abnormalities, on serum A-FABP concentrations
would be worth investigating in a prospective, interven-
tional study design.
The upregulation of A-FABP expression and other
adipokines in HF has also been demonstrated in recent
studies [3,4,29,30]. However, their exact roles in the
pathogenesis of HF remain unclear. The complex neuro-
hormonal and metabolic abnormalities associated
with HF have received increased attention. Of note,
upregulation of inflammatory cytokines, catecholamines,
growth hormone, and catabolic steroids is known to me-
diate increased lipolysis and insulin resistance [31]. Data
from randomized controlled trials of HF have suggested
a diabetes prevalence of 8% to 41%, and insulin resist-
ance is found to correlate with the functional, clinical,
and biochemical severity of HF [32]. Most importantly, a
recent in vitro study by Lamounier-Zepter et al. demon-
strated that A-FABP suppressed the contraction of
cardiomyocytes by attenuating intracellular Ca2+ levels
[33]. This offered strong evidence that A-FABP might be
directly involved in the pathogenesis of HF. In human
studies, Mingya et al. [29] demonstrated that serum
A-FABP levels were associated with HF severity, as de-
termined by the NYHA classification system, and were
positively correlated with NT-proBNP levels in Chinesetio for the risk of heart failure in patients with coronary
OR 95% CI P value
1.58 1.25 – 1.99 < 0.001
2.03 1.31 – 3.14 0.002
glucose, LDL-C,
ics and statins use
2.71 1.23 – 5.94 0.013
rs; BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; LDL-C,
ore.
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that plasma concentration of A-FABP predicted a
1.09-fold higher risk of heart failure during a median
follow-up of 10.7 years [30]. In our patients, the moder-
ate correlation between A-FABP and NT-proBNP levels
also suggested a link between A-FABP level and HF se-
verity. Because the association between A-FABP level
and CAD severity was attenuated in the subgroup of pa-
tients with HF and the predictive value of A-FABP to
HF persisted after adjustment for SRS and SSS, we be-
lieve that HF-related metabolic disarrangement, rather
than CAD severity, may be a more important determin-
ant of A-FABP levels in CAD patients with HF.
Notably, higher serum creatinine levels are observed
in moderate to severe CAD, with renal function being
the main independent predictor of circulating A-FABP
levels. Previous studies have shown a negative relation-
ship between GFR and A-FABP concentration, sugges-
ting that A-FABP might have an important role in the
interplay between renal dysfunction and the develop-
ment of coronary atherosclerosis [34]. Because A-FABP
is a low-molecular-weight plasma protein, freely filtered
at the glomerulus, a decrease in glomerular function will
result in an elevation of A-FABP concentration. In our
current study, A-FABP level remained an independent
predictor of myocardial perfusion abnormality, even
after adjusting for renal function.
There were some limitations in the present study.
First, the small number of patients enrolled was inad-
equate to obtain conclusive data. Second, owing to the
cross-sectional design of our study, some conclusions
were based on findings from association studies that did
not imply a direct causal relationship. Third, the SSS
could not accurately indicate the severity of CAD in a
small number of patients who underwent percutaneous
coronary angioplasty before SPECT analysis. However,
the myocardial scar, indicated by SRS, was not affected
by whether angioplasty had been performed.
Conclusions
In our study, the serum A-FABP levels not only were as-
sociated with myocardial perfusion abnormalities and
left ventricular function, but also predicted the presence
of HF in the CAD patients. In conjunction with previous
data, our results confirm the important role of A-FABP
in metabolic syndrome, atherosclerosis, and HF. How-
ever, a further large-scale, prospective study is needed to
confirm its predictive value upon traditional CAD risk
factors.
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